These findings highlight the role of EV‐mediated H3C14 excretion in regulating GCB resistance and suggest potential therapeutic strategies targeting EV pathways to overcome drug resistance in bladder cancer. This evidence concerns the gene H3C14 and urinary bladder cancer.